19 slides from Wuxi Apptec Co., Ltd. Class A's earnings presentation, Apr 29, 2026
Slide 1: WuXi AppTec Co., Ltd. 2026 First Quarterly Results Presentation
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in relia
Slide 2: WuXi AppTec First Quarterly 2026 Results
WuXi AppTec First Quarterly 2026 Results April 28, 2026 1
Slide 3: Forward-Looking Statements
Forward-Looking Statements This presentation may contain certain statements that are or may be forward looking, which can be recognized by the use of words such as “expects”, “plans”, “will”, “estimates”, “projects”, “intends”, or words of similar meaning. Such forward-looking statements are not his
Slide 4: Results Overview, Segment Performance, Financial Performance, Company Outlook
01 Results Overview 02 Segment Performance 03 Financial Performance 04 Company Outlook 3 Note: Unless otherwise stated, all financials disclosed in this presentation are prepared based on IFRS. The currency is RMB. All net profit disclosed in this presentation represents net profit attributable to t
Slide 5: 1. Results Overview
1. Results Overview Vv Wuxi AppTec
Slide 6: Q1 2026 Revenue & Profit Both Delivered Strong Growth
Q1 2026 Revenue & Profit Both Delivered Strong Growth; Revenue from Continuing Operations Up 39.4% YoY, and Adjusted Non-IFRS Net Profit Up 71.7% YoY Revenue Adjusted Non-IFRS Net Profit RMB billion RMB billion Adjusted Non-IFRS NPM Discontinued Operations Continuing Operations +28.8% +71.7% +39.4%1
Slide 7: Continue to Focus on Core CRDMO Strategy; Backlog Up 23.6% YoY
Continue to Focus on Our Core CRDMO Strategy, and Further Enhance Business Visibility, Backlog for Continuing Operations1 Up 23.6% YoY as of March 31, 2026 Backlog for Continuing Operations1 RMB billion +23.6% 59.77 58.00 56.26 53.04 48.36 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 6 Note: 1. As disclo
Slide 8: 2. Segment Performance
2. Segment Performance Vv Wuxi AppTec
Slide 9: WuXi Chemistry: Continuous Pipeline Expansion and Steady Late-stage Progression
WuXi Chemistry: Continuous Pipeline Expansion and Steady Late-stage Progression, While Accelerating Proactive Capacity Planning CRDMO Business Model Drives Continuous Growth Revenue & Gross Profit Margin Driven by steady pipeline progression to late stages, and the sequential ramp-up of new RMB bi
Slide 10: WuXi Chemistry: Follow the Molecule + Win the Molecule
WuXi Chemistry: “Follow the Molecule + Win the Molecule”, Small Molecule CRDMO Pipeline Efficiently Converts and Captures High-Quality Molecules, Delivering Sustained Growth “R” 420,000+compounds 14,751 Compounds Q1 2026 Newly Added Molecules to D&M Pipeline in Total 328 2,981 Preclinical & Phase I
Slide 11: WuXi Testing: Strengthening Differentiated Capabilities and Operational Management
WuXi Testing1: Strengthening Differentiated Capabilities and Operational Management; Drug Safety Evaluation Services Maintained Leading Position Revenue & Gross Profit Margin1 RMB billion WuXi Testing1 Q1 revenue up 27.4% YoY to 1.13bn. Notably, revenue of drug Adjusted Non- 24.8% 35.5% safety eva
Slide 12: WuXi Biology: Continues to Follow the Science & Generate Downstream Opportunities
WuXi Biology: Continues to Follow the Science & Generate Downstream Opportunities; In Vivo & In Vitro Synergies and Non-oncology Business Drove Growth Revenue & Gross Profit Margin WuXi Biology follows the science and strategically builds differentiated RMB billion capabilities of drug discovery i
Slide 13: 3. Financial Performance
3. Financial Performance Vv Wuxi AppTec
Slide 14: Continuously Drive Quality Growth, Further Enhancing Profitability
Continuously Drive Quality Growth, Strengthen Technological Expertise and Operational Efficiency, Leverage Management Resilience, Further Enhancing Profitability Adjusted Non-IFRS Gross Profit Adjusted Non-IFRS GPM* Adjusted Non-IFRS Net Profit Adjusted Non-IFRS NPM RMB billion RMB billion 38.0% 38.
Slide 15: Q1 2026 Adjusted Operating Cash Flow Up 21.7% YoY
With Sustained Business Growth, Enhanced Operational Efficiency and Financial Management, Q1 2026 Adjusted Operating Cash Flow1 Up 21.7% YoY to 3.69 Billion RMB billion 16.67 Adjusted Operating Cash Flow1 Capex2 12.64 11.99 9.97 10.23 6.94 5.52 5.54 4.38 4.00 3.69 Q1 2025 1.19 3.03 Q1 2025 0.73 2021
Slide 16: 4. Company Outlook
4. Company Outlook WW) Bestec
Slide 17: Company Outlook
Company Outlook Focus on the CRDMO business model, striving for highly efficient & exceptional services and operational excellence Continue to focus on our unique integrated CRDMO core business, and accelerate global expansion, capacity construction and capability development Leveraging customer
Slide 18: Company Outlook
Company Outlook Remain committed to rewarding shareholders and upholding the Company's value While accelerating global capacity and capability enhancement, the Company’s Board of Directors proposes (subject to approval by the Annual General Meeting) the 2026 total cash dividend distribution plan a
Slide 19: WuXi AppTec
Wuxi AppTec